Maryland 2023 Regular Session

Maryland House Bill HB811

Introduced
2/8/23  
Refer
2/8/23  
Report Pass
3/16/23  
Engrossed
3/20/23  
Refer
3/20/23  
Report Pass
3/31/23  
Enrolled
4/5/23  
Chaptered
5/3/23  

Caption

Hospitals - Testing for Fentanyl (The Josh Siems Act)

Impact

By instituting these testing requirements, HB811 is expected to significantly alter protocols within emergency medical settings. Hospitals will be forced to adapt their screening processes, potentially increasing the detection rates of fentanyl use among overdose patients. This could lead to improved outcomes through more tailored and immediate treatment strategies for those in crisis. Furthermore, the bill outlines the procedure for reporting test results to state health authorities, which will help in tracking the fentanyl crisis at a broader level and informing public health responses.

Summary

House Bill 811, known as The Josh Siems Act, mandates that hospitals' emergency departments perform rapid urine drug tests for the presence of fentanyl when treating individuals with known or suspected drug overdoses. This bill aims to enhance the response to the opioid crisis by ensuring that healthcare providers can quickly determine the involvement of fentanyl in overdoses, thereby facilitating timely and appropriate medical interventions. The requirement for fentanyl testing reflects growing concerns about the prevalence of this potent opioid in overdose situations across the state.

Sentiment

The sentiment surrounding HB811 is largely supportive from public health advocates and medical professionals, who recognize the need for better tools to combat the opioid epidemic. Proponents argue that timely fentanyl testing can save lives by allowing for quicker responses to overdose patients. However, some concerns have been raised regarding the potential for increased pressures on emergency departments and the adequacy of necessary testing resources in hospitals.

Contention

Despite the general support for the bill, notable points of contention include the feasibility of its implementation. Critics have raised questions about the resources available in hospitals to conduct rapid testing without delay, especially in facilities that may lack the necessary equipment or staffing. Additionally, while the bill seeks to enhance emergency response, it does not provide specific funding or support for hospitals to adapt their testing capabilities, which may pose challenges to effective enforcement.

Companion Bills

MD SB914

Crossfiled Hospitals - Testing for Fentanyl (The Josh Siems Act)

Previously Filed As

MD SB914

Hospitals - Testing for Fentanyl (The Josh Siems Act)

MD HB5456

HOSPITALS-FENTANYL TESTING

MD HB1626

HOSPITALS-FENTANYL TESTING

MD HB2742

Hospitals; urine drug screening to include testing for fentanyl.

MD SB1209

Hospitals; fentanyl testing

MD H1195

Fentanyl Testing

MD A4057

Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

MD S3274

Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

MD H2457

Relative to fentanyl testing

MD H745

Mandate Fentanyl Testing/Hospital ER Patients

Similar Bills

No similar bills found.